Current Report Filing (8-k)
October 10 2017 - 9:15AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): October 9, 2017
EXPRESS SCRIPTS HOLDING COMPANY
(Exact Name of Registrant as Specified in its Charter)
|
|
|
|
|
DELAWARE
|
|
001-35490
|
|
45-2884094
|
(State or Other Jurisdiction of
Incorporation or Organization)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
|
|
|
One Express Way, St. Louis, MO
|
|
63121
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
Registrants telephone number including area code:
314-996-0900
No change since last report
(Former Name or Address, if Changed Since Last Report)
Check the appropriate box below
if the Form
8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (
see
General Instruction A.2. below):
|
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
☐
|
Soliciting material pursuant to Rule
14a-12
under the Exchange Act (17 CFR
240.14a-12)
|
|
☐
|
Pre-commencement
communications pursuant to Rule
14d-2(b)
under the Exchange Act (17 CFR
240.14d-2(b))
|
|
☐
|
Pre-commencement
communications pursuant to Rule
13e-4(c)
under the Exchange Act (17 CFR
240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth company as
defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule
12b-2
of the Securities Exchange Act of 1934
(§240.12b-2
of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or
revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 7.01.
|
Regulation FD Disclosure
|
Attached as Exhibit 99.1 and incorporated by reference herein is a press
release dated October 10, 2017 issued by Express Scripts Holding Company (the Company).
The information provided pursuant to this Item
7.01 is being furnished and shall not be deemed to be filed with the Securities and Exchange Commission or incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as
amended, except to the extent set forth by specific reference in any such filing.
On October 9, 2017, the Company, Oz Parent, Inc., a wholly owned subsidiary of the
Company (Buyer), and certain of their subsidiaries (the Merger Subs) entered into a Transaction Agreement and Plan of Merger (the Merger Agreement) with CareCore National Group, LLC (CareCore) and
certain of its affiliates controlling the business known as eviCore healthcare. Pursuant to the Merger Agreement, upon the terms and subject to the conditions thereof, the Merger Subs will merge with into CareCore and certain of its affiliates such
that eviCore healthcare will be owned, directly or indirectly by Buyer and the Company.
The transaction is subject to customary regulatory approvals and
closing conditions and is expected to close in the fourth quarter of 2017.
Item 9.01
|
Financial Statements and Exhibits
|
(d) The following Exhibit is furnished as part
of this report on Form
8-K.
|
|
|
Exhibit 99.1
|
|
Press Release, dated October 10, 2017.
|
EXHIBIT INDEX
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned
thereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
EXPRESS SCRIPTS HOLDING COMPANY
|
|
|
|
|
Date: October 10, 2017
|
|
|
|
By:
|
|
/s/ Martin Akins
|
|
|
|
|
|
|
Martin Akins
|
|
|
|
|
|
|
Senior Vice President and General Counsel
|
Express Scripts Holding Company (delisted) (NASDAQ:ESRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Express Scripts Holding Company (delisted) (NASDAQ:ESRX)
Historical Stock Chart
From Apr 2023 to Apr 2024